MX2022001027A - Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo. - Google Patents

Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo.

Info

Publication number
MX2022001027A
MX2022001027A MX2022001027A MX2022001027A MX2022001027A MX 2022001027 A MX2022001027 A MX 2022001027A MX 2022001027 A MX2022001027 A MX 2022001027A MX 2022001027 A MX2022001027 A MX 2022001027A MX 2022001027 A MX2022001027 A MX 2022001027A
Authority
MX
Mexico
Prior art keywords
egfr
antibody
biaspecific
treating
pharmaceutical composition
Prior art date
Application number
MX2022001027A
Other languages
English (en)
Spanish (es)
Inventor
Na Rae Lee
Moo Young Song
Eunsil Sung
Jaehyun Eom
Yeunju Kim
Youngdon Pak
Young Bong Park
Yangsoon Lee
Hyejin Chung
Minji Park
Hyoju Choi
Yeryoung Yong
Ui-Jung Jung
Kyeongsu Park
Wonjun Son
Youngkwang Kim
Eun-Jung Lee
Eun Jung Lee
Original Assignee
Abl Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abl Bio Inc filed Critical Abl Bio Inc
Publication of MX2022001027A publication Critical patent/MX2022001027A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2022001027A 2019-07-26 2020-07-27 Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo. MX2022001027A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962878977P 2019-07-26 2019-07-26
PCT/KR2020/009870 WO2021020845A1 (en) 2019-07-26 2020-07-27 Anti-egfr/anti-4-1bb bispecific antibody and use thereof

Publications (1)

Publication Number Publication Date
MX2022001027A true MX2022001027A (es) 2022-04-18

Family

ID=74189704

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001027A MX2022001027A (es) 2019-07-26 2020-07-27 Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo.

Country Status (11)

Country Link
US (2) US12168690B2 (enExample)
EP (1) EP4004053A4 (enExample)
JP (2) JP7738545B2 (enExample)
KR (1) KR20220038767A (enExample)
CN (2) CN118221825A (enExample)
AU (1) AU2020320349A1 (enExample)
BR (1) BR112022001329A2 (enExample)
CA (1) CA3147420A1 (enExample)
MX (1) MX2022001027A (enExample)
WO (1) WO2021020845A1 (enExample)
ZA (1) ZA202200905B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11261259B2 (en) 2019-08-12 2022-03-01 I-Mab Biopharma Us Limited Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof
WO2022072087A1 (en) * 2020-10-01 2022-04-07 QC Ware Corp. Quantum number preserving circuits for preparing quantum states representing fermions in computational units-based quantum computers
JP7767613B2 (ja) 2021-11-15 2025-11-11 システィミューン，インコーポレイテッド 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用
CN118369340A (zh) * 2021-11-25 2024-07-19 盛禾(中国)生物制药有限公司 一种双特异性抗原结合蛋白
EP4504790A4 (en) * 2022-04-07 2026-04-08 Yuhan Corp Pharmaceutical composition for treating or preventing cancer with low HER2 expression
WO2024143643A1 (ko) * 2022-12-30 2024-07-04 앱클론(주) Cd137에 특이적으로 결합하는 어피바디 및 이의 용도
KR20240164748A (ko) * 2023-05-12 2024-11-20 앱클론(주) 항체 또는 그의 항원 결합 단편, 및 어피바디를 포함하는 이중 항원 표적 단백질 복합체
KR102927129B1 (ko) 2025-03-18 2026-02-11 이트너스 주식회사 임직원 공간 산정을 위한 사무 및 부대 시설 면적 계산 솔루션

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69624436T2 (de) 1995-04-08 2003-08-28 Lg Chemical Ltd., Seoul/Soul Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
BRPI0607315B1 (pt) 2005-02-07 2022-05-17 Roche Glycart Ag Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
WO2008028686A2 (en) * 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
US20140178368A1 (en) 2011-04-19 2014-06-26 Leslie Lynne SHARP Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
KR102319582B1 (ko) * 2013-08-16 2021-11-04 메모리얼 슬로안 케터링 캔서 센터 선택적 ｇｒｐ９４ 저해제 및 이의 용도
US10717783B2 (en) * 2014-12-22 2020-07-21 Zeren Gao Bispecific tetravalent antibodies and methods of making and using thereof
ES2819870T3 (es) 2015-09-30 2021-04-19 Igm Biosciences Inc Moléculas de unión con cadena J modificada
SG11201808196UA (en) 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
BR112018071612A2 (pt) * 2016-04-22 2019-02-19 Alligator Bioscience Ab polipeptídeos biespecíficos inovadores contra cd137
JP7160833B2 (ja) * 2017-04-13 2022-10-25 サイロパ ビー．ブイ． 抗ｓｉｒｐアルファ抗体
US11725060B2 (en) 2017-07-20 2023-08-15 Aptevo Reserch and Development LLC Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods
JP2021508478A (ja) * 2017-12-28 2021-03-11 ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクＪｕｌｉｕｓ Ｍａｘｉｍｉｌｉａｎｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｗｕｅｒｚｂｕｒｇ ＦｃγＲ非依存性アゴニスト活性がある腫瘍壊死因子（ＴＮＦ）受容体スーパーファミリー（ＴＮＦＲＳＦ）受容体活性化抗体融合タンパク質（ＦｃγＲ非依存性アゴニスト活性があるＴＮＦＲＳＦ受容体活性化抗体融合タンパク質；ＴＲＡＡＦＦＩＡＡ）
EP3880247A4 (en) * 2018-11-13 2022-10-26 JN Biosciences, LLC Bispecific antibodies for activation of immune cells
SG11202105152YA (en) * 2018-11-30 2021-06-29 Abl Bio Inc Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
US11261259B2 (en) * 2019-08-12 2022-03-01 I-Mab Biopharma Us Limited Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof
CN115190889A (zh) * 2020-02-28 2022-10-14 上海复宏汉霖生物技术股份有限公司 抗cd137构建体、多特异性抗体及其用途

Also Published As

Publication number Publication date
WO2021020845A1 (en) 2021-02-04
US20210024638A1 (en) 2021-01-28
JP7738545B2 (ja) 2025-09-12
CN118221825A (zh) 2024-06-21
KR20220038767A (ko) 2022-03-29
EP4004053A4 (en) 2023-10-18
US12168690B2 (en) 2024-12-17
JP2026004296A (ja) 2026-01-14
BR112022001329A2 (pt) 2022-03-22
CN114450306A (zh) 2022-05-06
US20250066487A1 (en) 2025-02-27
CN114450306B (zh) 2024-04-05
ZA202200905B (en) 2023-11-29
CA3147420A1 (en) 2021-02-04
EP4004053A1 (en) 2022-06-01
JP2022542670A (ja) 2022-10-06
AU2020320349A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
MX2022001022A (es) Anticuerpo biespecifico anti-her2/anti-4-1bb y uso del mismo.
ZA202200905B (en) Anti-egfr/anti-4-1bb bispecific antibody and use thereof
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CO2022005077A2 (es) Compuestos moduladores de glp-1r
LT4067387T (lt) Anti-pd-1-anti-vegfa bispecifinis antikūnas, farmacinė kompozicija ir jos panaudojimas
CL2021000458A1 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr (divisional de solicitud 201602359)
NZ795278A (en) Antibody-pyrrolobenzodiazepine derivative conjugate
UY38353A (es) Inhibición de integrina alfavbeta6
MX2019013858A (es) Inhibidores de kras g12c y metodos para su uso.
MX2020008977A (es) Formulaciones de anticuerpos de her2 subcutaneas.
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
PH12022550646A1 (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
ZA202211405B (en) Anti-cd73-anti-pd-1 bispecific antibody and use thereof
MX2024012294A (es) RECEPTORES DE TGF-ß Y MÉTODOS DE USO
BR112015032718A2 (pt) composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
BR112022008558A2 (pt) Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso
CL2021001739A1 (es) Inhibidores de la proteína de activación de fibroblastos.
WO2018009507A8 (en) COMBINATION OF A TIM -4 ANTAGONIST AND METHODS OF USE
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2024002261A (es) Molecula de union de fap/cd40 y uso medicinal de la misma.
MX2019010060A (es) Composiciones y metodo para tratar cancer.
ZA202309150B (en) Antibody against nkp46 and application of antibody
BR112022012731A2 (pt) Anticorpo anti-ox40 e uso do mesmo
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.